AMGEN Q1 2026 TEPEZZA (teprotumumab-trbw) sales increased 29% year-over-year to $490 million in the first quarter, driven by a 22% impact from higher inventory levels and higher net selling price. https://www.amgen.com/newsroom/press-releases/2026/04/c-o-r-r-e-c-t-i-o-n----amgen
Genmab Appoints Margarida Duarte as General Manager, Europe and Emerging Markets https://ir.genmab.com/news-releases/news-release-details/genmab-appoints-margarida-duarte-general-manager-europe-and-emerging-markets
Wells Fargo initiated coverage of Genmab with an Overweight rating and $40 price target. The firm believes the company's upcoming Epkinly and petosemtamab readouts are "largely de-risked" based on the Ph2 data. In addition, Genmab shares at current levels do not reflect petosemtamab's potential beyond head and neck cancer, sees 2026 as 'inflection year' with multiple catalysts.
Reelt er det kun solide der er floppet - selv dette er ikke sikkert. De har succes i deres pipeline og den udvikler sig hver dag. Dara sælger som ledelsen har lovet. Markedet er ikke altid rationelt - men ærgeligt hvis man sælger med tab nu.
Doing Great Two Years on My Epcoritamab Trial: Time to Stop? https://cllsociety.org/2025/06/doing-great-two-years-on-my-epcoritamab-trial-time-to-stop/
